Table 4.
Clinical studies for evaluation of Hydroxychloroquine (https://clinicaltrials.gov/ct2/results).
| Clinical Trial Number | Study Description | Phase | Dose | Location |
|---|---|---|---|---|
| NCT04345692 | A Randomized Controlled Clinical Study utilizing Hydroxychloroquine for Treating Hospitalized Patients | 3 | 400 mg two times a day 1, then 200 mg two times a day for days 2–5 | United States |
| NCT04340544 | Utilization of Hydroxychloroquine for the Treatment of Mild COVID-19 Disease | 3 | 600 mg daily for 7 days | Germany |
| NCT04349228 | Assessing the Efficacy and Safety of Hydroxychloroquine as a Prophylactic therapeutic for Health Professionals against COVID19 | 3 | 200 mg/day | Tunisia |
| NCT04328272 | Effectiveness of Hydroxychloroquine in Covid-19 Patients | 3 |
Day1: 3 tablets (200 mg per tablet), after 6 h, 3 tablets (200 mg per tablet) Day2-7: (maintenance dose), 2 tablets twice a day. |
Pakistan |
| NCT04359953 | Efficacy of Hydroxychloroquine, Telmisartan, and Azithromycin for Elder Patients | 3 | 200 mg two times a day for 2 weeks | France |
| NCT04342221 | Hydroxychloroquine for COVID-19 | 3 |
Day 1:800 mg Day2 onwards: 600 mg (3 capsules) one time a day |
Germany |
| NCT04318015 | Hydroxychloroquine as a Chemoprophylactic therapeutic for Healthcare Personnel who have come in Contact With COVID-19 infected individuals | 3 | 200 mg per day for 60 days. | Mexico |
| NCT04332991 | Evaluation of Outcomes associated with COVID-19 when Treatment With Hydroxychloroquine Among Symptomatic patients was done | 3 | 400 mg two times a day, 200 mg two times a day for the following 4 days | United States |